Strategy & Due Diligence in Pharma Business Development
Pharma growth depends on smarter BD decisions. This article outlines a clear framework to evaluate external opportunities before committing to formal diligence.
drug development
-
-
Scientific insights: CKD
VibeOne analyzed 100+ CKD programs and found a clear pattern: small molecules dominate and repurposed drugs win. The next kidney breakthrough may already be in a cardiovascular trial.
-
Scientific insights:The ActRIIB Challenge (LAE103)
The obesity market is undergoing a quiet revolution: it’s no longer about how much weight patients lose, but what kind of weight they lose.
-
Scientific insights: Urea cycle disorders
Drug hunters need to watch Urea Cycle Disorders! Gene therapies (cost) and ERTs (patient experience) still leave much to be desired.
-
Increasing hope in rare disease — how Incite partnered with Vibe Bio to accelerate the search & evaluation of sarcoma drugs
Learn how Incite partnered with Vibe Bio to accelerate sarcoma drug discovery with unbiased ranking and AI-powered compound analysis.
-
How Orphan Therapeutics Accelerator is optimizing rare disease search & eval
Learn how Orphan Therapeutics Accelerator uses Vibe Bio for rare disease due diligence, pipeline and competitive analysis, and in-licensing strategy.
-
Improving biopharma BD with AI-powered due diligence
In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints.
-
Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
-
The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development.
-
5 insights from JPM 2025
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
